Table 1 Listings of infections with overall incidence in > 5% of patients with PTCL or CTCL
From: Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma
| Â | Total AEs | Drug-related AEs | ||
|---|---|---|---|---|
Subgroup | All grade | grade ≥ 3 | All grade | Grade ≥ 3 |
Cellulitis, n (%) | Â | Â | Â | Â |
 PTCL | 6 (5) | 5 (4) | 3 (2) | 3 (2) |
 CTCL | 2 (2) | 0 | 0 | 0 |
Pneumonia, n (%) | ||||
 PTCL | 8 (6) | 6 (5) | 2 (2) | 2 (2) |
 CTCL | 1 (0) | 0 | 0 | 0 |
Sepsis, n (%) | Â | Â | Â | Â |
 PTCL | 7 (5) | 7 (5) | 2 (2) | 2 (2) |
 CTCL | 4 (4) | 4 (4) | 2 (2) | 2 (2) |
Nasopharyngitis, n (%) | Â | Â | ||
 PTCL | 6 (5) | 0 | 0 | 0 |
 CTCL | 4 (4) | 0 | 0 | 0 |
Upper respiratory tract infection, n (%) | Â | Â | ||
 PTCL | 11 (8) | 2 (2) | 7 (5) | 2 (2) |
 CTCL | 6 (6) | 0 | 1 (1) | 0 |
Urinary tract infection, n (%) | Â | Â | ||
 PTCL | 9 (7) | 1 (1) | 2 (2) | 1 (1) |
 CTCL | 3 (3) | 0 | 1 (1) | 0 |
Skin infection, n (%) | Â | Â | ||
 PTCL | 2 (2) | 0 | 1 (1) | 0 |
 CTCL | 7 (7) | 1 (1) | 2 (2) | 0 |